

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1477)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2024

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the Annual General Meeting.

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”) is pleased to announce the poll results of the annual general meeting of the Company (the “**Annual General Meeting**”) held at 56th Floor, One Museum Place Office Building, No. 669 Xinzha Road, Shanghai, PRC on Thursday, June 20, 2024 at 10:00 a.m.

References are made to the Company’s circular (the “**Circular**”) in connection with the Annual General Meeting and notice of the Annual General Meeting (the “**Notice**”) both dated May 24, 2024. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Annual General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and auditor for the year ended December 31, 2023.	425,220,462 (100.000000%)	0 (0.000000%)
2.	(a) To re-elect the following retiring Directors:		
	(i) Dr. Lian Yong CHEN as a non-executive Director	420,291,939 (98.840949%)	4,928,523 (1.159051%)
	(ii) Dr. Wei LI as a non-executive Director	424,999,696 (99.948082%)	220,766 (0.051918%)
	(iii) Mr. Yanling CAO as a non-executive Director	424,999,696 (99.948082%)	220,766 (0.051918%)
	(b) To authorize the Board of to fix the remuneration of the Directors.	425,118,342 (99.975984%)	102,120 (0.024016%)
3.	To re-appoint Deloitte Touche Tohmatsu as the auditor of the Company and authorize the Board to fix their remuneration.	425,220,462 (100.000000%)	0 (0.000000%)
4.	(A) To give a general mandate to the Directors to allot, issue and deal with additional shares (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the issued shares of the Company (excluding treasury shares) as of the date of this resolution.	386,918,710 (90.992496%)	38,301,752 (9.007504%)
	(B) To give a general mandate to the Directors to repurchase shares not exceeding 10% of the issued shares of the Company (excluding treasury shares) as of the date of this resolution.	425,220,462 (100.000000%)	0 (0.000000%)
	(C) To extend the authority given to the Directors pursuant to ordinary resolution no. 4(A) to issue shares by adding to the issued shares of the Company (excluding treasury shares) the number of shares repurchased under ordinary resolution no. 4(B).	385,579,210 (90.677482%)	39,641,252 (9.322518%)

Ordinary Resolutions			Number of Votes (%)	
			For	Against
5.	(A)	To consider and adopt the proposed amendments to the 2021 share option scheme of the Company adopted on August 31, 2021 (the “ Proposed Amendments to the 2021 Share Option Scheme ”) and authorize Directors to execute all such documents and do all such other acts and things as he/she/they may, in his/her/their absolute discretion, consider necessary, desirable or expedient to effect the Proposed Amendments to the 2021 Share Option Scheme and any of the foregoing.	387,379,210 (91.100792%)	37,841,252 (8.899208%)
	(B)	To consider and adopt the proposed amendments to the 2021 share award scheme of the Company adopted on July 2, 2021 and amended on December 3, 2021 (the “ Proposed Amendments to the 2021 Share Award Scheme ”) and authorize Directors to execute all such documents and do all such other acts and things as he/she/they may, in his/her/their absolute discretion, consider necessary, desirable or expedient to effect the Proposed Amendments to the 2021 Share Award Scheme and any of the foregoing.	387,498,097 (91.128751%)	37,722,365 (8.871249%)
<p>As more than 50% of the votes were cast in favor of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Annual General Meeting.</p>				

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

The total number of issued Shares as of the date of the Annual General Meeting was 693,654,850 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all resolutions. As of the date of the Annual General Meeting, there were (i) no treasury Shares held by the Company (including any treasury Shares held or deposited with CCASS) and as such no voting rights of treasury Shares have been exercised at the Annual General Meeting; and (ii) no Shares repurchased by the Company which are pending cancellation and should be excluded from the total number of Shares for the purpose of the Annual General Meeting. There were no Shares entitling the holders to attend and abstain from voting in favor at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting. No Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the Annual General Meeting and no Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the Annual General Meeting.

The executive Directors, Mr. Ye LIU and Dr. Zhaopeng HU, the non-executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI and Mr. Yanling CAO and the independent non-executive Directors, Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG attended the Annual General Meeting, either in person or by means of telecommunication, whereas Ms. Yumeng WANG, a non-executive Director, was unable to attend the Annual General Meeting due to her other work arrangement at the time of such meeting.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 20, 2024

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.